CytomX Therapeutics (CTMX) Cash from Investing Activities (2014 - 2026)

CytomX Therapeutics has reported Cash from Investing Activities for 13 years, with the latest figure at -$192.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 730.07% year-over-year to -$192.8 million; the trailing twelve-month figure through Mar 2026 stood at -$283.1 million (down 431.48% YoY), and the FY2025 full-year result was -$59.7 million, down 159.92% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$192.8 million, down from -$14.4 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $99.8 million in Q4 2022, with the low at -$192.8 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$12.1 million across 5 years, with a median of $439000.0 in 2025.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 40842.04% — and 2023, when it slumped 19824.18%.
• CytomX Therapeutics' Cash from Investing Activities stood at $99.8 million in 2022, then slumped by 87.11% to $12.9 million in 2023, then gained by 17.64% to $15.1 million in 2024, then tumbled by 195.27% to -$14.4 million in 2025, then plunged by 1236.97% to -$192.8 million in 2026.
• The last three Cash from Investing Activities figures came in at -$192.8 million (Q1 2026), -$14.4 million (Q4 2025), and $439000.0 (Q3 2025), per Business Quant data.